FDA APPROVES FIRST BIOSIMILAR FOR CANCER

摘要

The US Food and Drug Administration (FDA) has approved a biosimilar of Avastin (bevacizumab) for multiple cancer indications. The product, known as MVASI (bevacizumab-awwb), is the first biosimilar to be approved for cancer in the USA.